Trial Profile
A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs DI Leu16 IL2 (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Alopexx Oncology
- 02 Nov 2020 Status changed from recruiting to discontinued as clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.
- 06 Dec 2016 Results (n=22) reporting maximum tolerated dose, optimal biologic dose and recommended phase 2 dose of subcutaneously administered DI-Leu16-IL2 in patients with relapsed or refractory CD20+ B-cell lymphoma, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Results of phase I trial were presented at the 58th annual American Society of Hematology (ASH) meeting, according to an Alopexx media release